NRX Pharmaceuticals, Inc. NRXP 深 沪
等待开盘 01-09 09:30:00 美东时间
2.33
-0.120
-4.90%
华盛通- 最 高2.445
- 今 开2.43
- 成交量 48.50万股
- 最 低 2.29
- 昨 收 2.45
- 总市值 6546.74万
- 52周最高 4.02
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.58
- 委 比 85.90%
- 总股本 2809.76万
- 历史最高 769.90
- 量 比 0.68
- 振 幅 6.33%
- 历史最低 1.58
- 每 手 1
- 风险率 0.58%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅36.7%！LMRI获多家大行首予超配评级； 瑞银下调甲骨文目标价从325美元至280美元
今日重点评级关注：HC Wainwright & Co.：维持Assertio Holdings"买入"评级，目标价从3美元升至35美元；HC Wainwright & Co.：维持万达生物制药"买入"评级，目标价从20美元升至22美元
01-06 17:52
美股大行评级 | 杰富瑞上调百度目标价从159美元升至181美元；花旗下调京东目标价从44美元下调至37美元
今日重点评级关注：Ascendiant Capital：维持NRX Pharmaceuticals"买入"评级，目标价从47美元升至48美元；BTIG：维持Hudson Pacific Properties"买入"评级，目标价从4.75美元升至26美元
01-05 13:52
Ulta Beauty To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a comple...
01-02 21:26
Ascendiant Capital Maintains Buy on NRX Pharmaceuticals, Raises Price Target to $48
Ascendiant Capital analyst Edward Woo maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and raises the price target from $47 to $48.
01-02 17:50
美股大行评级 | 潜在涨幅263.64%！Milestone Pharmaceuticals获富国银行升目标价至8美元，维持"超配"评级
今日重点评级关注：富国银行：维持Milestone Pharmaceuticals"超配"评级，目标价从4美元升至8美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从31美元升至33美元
2025-12-17 10:46
HC Wainwright & Co. Reiterates Buy on NRX Pharmaceuticals, Maintains $40 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $40 price target.
2025-12-16 20:09
美股大行评级 | 美鹰服饰、CrowdStrike、迈威尔科技获多家机构上调目标价；ACHC、GitLab、Okta遭多家机构下调目标价
今日重点评级关注：Guggenheim：维持Cybin Inc. Common Shares"买入"评级，目标价从39美元升至48美元；HC Wainwright & Co.：维持Capricor Therapeutics"买入"评级，目标价从24美元升至60美元
2025-12-04 09:38
美股大行评级 | 最高500美元！MongoDB获18家大行紧急上调目标价；巴克莱下调理想汽车目标价至18美元
今日重点评级关注：B. Riley证券：维持Seabridge Gold"买入"评级，目标价从50美元升至65美元；HC Wainwright & Co.：维持TRX Gold"买入"评级，目标价从1.2美元升至1.4美元
2025-12-03 09:58
D. Boral Capital Maintains Buy on NRX Pharmaceuticals, Maintains $34 Price Target
D. Boral Capital analyst Jason Kolbert maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $34 price target.
2025-12-02 23:20
NRx Pharmaceuticals (NASDAQ:NRXP) and HOPE Therapeutics to Present at NobleCon21 - Noble Capital Markets’ Twenty First Annual Emerging Growth Equity Conference
NRx Pharmaceuticals' CEO, Jonathan Javitt, will present at NobleCon21 on December 3, 2025, discussing the company's progress in developing investigational drugs, medical devices, and therapies for suicidal depression, PTSD, and related conditions. Interested investors can register at a discounted rate using code NRXPNOBLECON. A webcast of the presentation will be available on the company's website and Noble's platforms for 90 days. NRx is focused...
2025-12-01 13:03
